Cresset Asset Management LLC Reduces Stake in Danaher Corporation $DHR

Cresset Asset Management LLC lowered its position in Danaher Corporation (NYSE:DHR) by 15.2% in the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 42,014 shares of the conglomerate’s stock after selling 7,502 shares during the period. Cresset Asset Management LLC’s holdings in Danaher were worth $8,626,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. Fayez Sarofim & Co raised its position in shares of Danaher by 0.6% in the 4th quarter. Fayez Sarofim & Co now owns 8,287 shares of the conglomerate’s stock worth $1,902,000 after acquiring an additional 50 shares in the last quarter. Coastal Bridge Advisors LLC raised its position in shares of Danaher by 4.8% in the 4th quarter. Coastal Bridge Advisors LLC now owns 1,099 shares of the conglomerate’s stock worth $252,000 after acquiring an additional 50 shares in the last quarter. MGO One Seven LLC increased its position in Danaher by 1.3% during the 4th quarter. MGO One Seven LLC now owns 4,285 shares of the conglomerate’s stock valued at $984,000 after buying an additional 53 shares in the last quarter. Hills Bank & Trust Co increased its position in Danaher by 0.3% during the 1st quarter. Hills Bank & Trust Co now owns 18,015 shares of the conglomerate’s stock valued at $3,693,000 after buying an additional 53 shares in the last quarter. Finally, Sageworth Trust Co increased its position in Danaher by 2.3% during the 1st quarter. Sageworth Trust Co now owns 2,404 shares of the conglomerate’s stock valued at $493,000 after buying an additional 54 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on DHR shares. Wall Street Zen raised Danaher from a “hold” rating to a “buy” rating in a research report on Friday, June 27th. UBS Group reduced their price objective on Danaher from $240.00 to $225.00 and set a “buy” rating for the company in a research report on Wednesday, July 23rd. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $250.00 price objective on shares of Danaher in a research report on Wednesday, April 23rd. TD Cowen raised their price objective on Danaher from $240.00 to $248.00 and gave the company a “buy” rating in a research report on Wednesday, April 23rd. Finally, HSBC reduced their price objective on Danaher from $270.00 to $240.00 in a research report on Friday, April 25th. Three equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $247.61.

Danaher Stock Performance

DHR stock opened at $210.84 on Monday. The company has a market cap of $150.97 billion, a P/E ratio of 44.86, a price-to-earnings-growth ratio of 2.94 and a beta of 0.73. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $279.90. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. The stock’s fifty day moving average price is $199.94 and its 200-day moving average price is $199.54.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.64 by $0.16. The firm had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%. The company’s revenue for the quarter was up 3.4% on a year-over-year basis. During the same period last year, the business posted $1.72 EPS. On average, equities analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.